Because of the limited expression profile of PKCθ to some solid tumors and immune cells, and the fact that HSF1 is often overexpressed in tumors, TZL might only be lethal to PKCθ-expressing, HSF1- addicted glycolytic tumor cells. Here, PRRT2 is linked to neoplasm.